[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immunitybio Inc (IBRX)

Immunitybio Inc (IBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,378,832
  • Shares Outstanding, K 1,047,354
  • Annual Sales, $ 113,290 K
  • Annual Income, $ -351,400 K
  • EBIT $ -261 M
  • EBITDA $ -246 M
  • 60-Month Beta 0.02
  • Price/Sales 73.68
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 109.81% (-0.12%)
  • Historical Volatility 72.90%
  • IV Percentile 64%
  • IV Rank 37.92%
  • IV High 182.84% on 01/20/26
  • IV Low 65.20% on 12/30/25
  • Expected Move (DTE 3) 0.65 (8.18%)
  • Put/Call Vol Ratio 0.12
  • Today's Volume 21,089
  • Volume Avg (30-Day) 29,632
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 587,180
  • Open Int (30-Day) 630,417
  • Expected Range 7.35 to 8.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.09
  • Number of Estimates 2
  • High Estimate $-0.08
  • Low Estimate $-0.09
  • Prior Year $-0.10
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.73 +18.87%
on 04/29/26
8.69 -7.94%
on 05/11/26
+0.30 (+3.90%)
since 04/17/26
3-Month
6.54 +22.32%
on 03/24/26
12.43 -35.64%
on 02/25/26
-0.54 (-6.32%)
since 02/18/26
52-Week
1.95 +310.26%
on 12/31/25
12.43 -35.64%
on 02/25/26
+5.16 (+181.69%)
since 05/16/25

Most Recent Stories

More News
ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026

NAI+BCG versus Nadofaragene Results: NAI+BCG treated patients were twice as likely to achieve a complete response (CR) at any point of the study versus nadofaragene...

IBRX : 8.00 (+0.38%)
ImmunityBio, Inc. Deadline: IBRX Investors with Losses in Excess of $100K Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

NEW YORK , May 18, 2026 /PRNewswire/ -- 

IBRX : 8.00 (+0.38%)
IBRX 8-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims -- Hagens Berman

SAN FRANCISCO , May 18, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio...

IBRX : 8.00 (+0.38%)
ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035

Five issued U.S. patents cover the combination of ImmunityBio’s IL-15 receptor agonist (NAI) with Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer treatment, with terms extending...

IBRX : 8.00 (+0.38%)
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States

Positive Phase III readout of National Cancer Institute sponsored SWOG S1602 randomized clinical trial demonstrating non-inferior efficacy of the Tokyo strain of BCG (Tokyo-172 BCG) versus TICE BCG in...

IBRX : 8.00 (+0.38%)
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX

NEW ORLEANS , May 15, 2026 /PRNewswire/ -- ClaimsFiler , a FREE shareholder information service, reminds investors that they have until May 26, 2026  to file lead plaintiff applications...

IBRX : 8.00 (+0.38%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines - IBRX

NEW YORK , May 14, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX).   Such investors...

IBRX : 8.00 (+0.38%)
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit

Did you buy IBRX securities between January 19, 2026, and March 24, 202 6?

IBRX : 8.00 (+0.38%)
IBRX 12-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims -- Hagens Berman

SAN FRANCISCO , May 14, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio...

IBRX : 8.00 (+0.38%)
IBRX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their Options

IBRX : 8.00 (+0.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ImmunityBio Inc. is a late-clinical-stage immunotherapy company developing therapies which drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems. ImmunityBio Inc., formerly known as NantKwest...

See More

Key Turning Points

3rd Resistance Point 9.23
2nd Resistance Point 8.88
1st Resistance Point 8.44
Last Price 8.00
1st Support Level 7.65
2nd Support Level 7.30
3rd Support Level 6.86

See More

52-Week High 12.43
Fibonacci 61.8% 8.43
Last Price 8.00
Fibonacci 50% 7.19
Fibonacci 38.2% 5.95
52-Week Low 1.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.